Moderna starts trial with ommicron-specific COVID-19 vaccine


Moderna gave its ommicron-specific COVID-19 vaccine to its first clinical trial participant, the company announced Wednesday. The report comes a few days after Pfizer/BioNTech launched a trial of its shot targeting the fast-spreading variant.

The announcement coincides with the release of data showing that the two-dose series of Moderna’s original vaccine struggled to block the omicron variant of the virus, which has mutations that help it evade those antibodies. A booster shot restored much of its ability to neutralize the virus — and while that protection weakened over time, it lingered for at least another six months.

Still, Moderna’s CEO, Stéphane Bancel, said in a statement that the omicron variant poses a sufficient threat that the company plans to move forward with the variant booster.

The company is testing its ommicron booster in one group of people who received only a two-dose series of the original vaccine and a second group who had a two-dose series and a booster of the original vaccine. There will be approximately 300 participants per group.

Bancel said in early January that Moderna could have data on the ommicron booster ready by March.

Leave a Reply

Your email address will not be published.